Proteomic analysis reveals a 4-methylumbelliferone-induced metabolic shift accompanied by reduced CD147 expression and MMP-2 activity in U937 cells

Imagine your body as a bustling city where every cell is a worker with a specific job. Sometimes, a group of workers goes rogue, multiplying uncontrollably and taking over the city's resources. This is what happens in Acute Myeloid Leukemia (AML), a type of blood cancer where immature cells crowd out healthy ones, often leading to a situation where standard treatments stop working. To fight this, scientists look for "drug repositioning"—a clever strategy where they take a medicine already approved for one job (like stopping muscle cramps) and see if it can do a new job, like fighting cancer.

One such candidate is a molecule called 4-methylumbelliferone, or 4MU for short. Think of 4MU as a construction foreman that usually stops the building of a sticky, gooey substance called hyaluronic acid (HA). In many cancers, this goo acts like a scaffold that helps tumors grow and spread, so blocking it is a common strategy. However, scientists have noticed that 4MU sometimes stops cancer cells from growing even when it doesn't stop the goo from being built. This raises a fascinating question: if the "goo-blocking" isn't the reason 4MU works in these cases, what secret weapon is it using instead? To solve this mystery, researchers needed to look inside the cells to see which proteins were changing, essentially taking a snapshot of the cell's internal machinery to find the real culprit.

In this study, the researchers focused on a specific type of leukemia cell called U937. They knew that in these cells, 4MU stops them from multiplying, but it doesn't actually stop them from making hyaluronic acid. This made U937 the perfect "test kitchen" to discover 4MU's hidden, HA-independent tricks. The team used a high-tech method called proteomics, which is like a massive inventory check of all the proteins (the cell's tools and workers) present in the cell. They treated the cells with 4MU and compared the protein list to untreated cells.

The results revealed a major shift in how the cells were running their power plants. The researchers found that 4MU didn't just tweak one thing; it caused a metabolic overhaul. Normally, these cancer cells run like gas-guzzling cars, relying heavily on a quick-and-dirty energy process called glycolysis. But after 4MU treatment, the cells were forced to switch to a more efficient, oxygen-dependent engine called OXPHOS. It's as if the drug kicked the cells out of their comfortable, fast-food energy diet and forced them to start eating a healthy, complex meal that required more effort to digest. The cells also started using different fuel sources, like fats and amino acids, to keep running.

To confirm this energy shift, the team used a specialized test called SCENITH, which acts like a stress test for the cell's power grid. They blocked different energy pathways to see which one the cells relied on most. The test confirmed that 4MU-treated cells were much less dependent on their old glycolytic habit and had become more reliant on their mitochondria (the cell's batteries) and other fuel sources.

But the story didn't stop at energy. The researchers noticed that one specific protein, CD147, was missing from the 4MU-treated cells. CD147 is like a "boss" protein that sits on the cell's surface and helps organize the cell's energy systems and its ability to break through barriers. The team used flow cytometry (a machine that counts and sorts cells based on glowing tags) and immunofluorescence (taking glowing photos of the cells) to prove that 4MU significantly reduced the amount of CD147 on the cell surface.

Why does losing CD147 matter? Because CD147 is known to team up with an enzyme called MMP-2, which acts like a pair of molecular scissors. These scissors help cancer cells cut through the tissue around them to spread to other parts of the body. The researchers found that when 4MU lowered the levels of CD147, the activity of these "scissors" (MMP-2) also dropped. This suggests that by removing the boss (CD147), 4MU also disarms the scissors, potentially making it harder for the cancer to spread.

The team also looked at data from real patients with AML. While the numbers didn't show a statistically perfect link between high CD147 levels and survival in their specific analysis, there was a noticeable trend: patients with higher levels of this protein tended to have shorter survival times. This hints that CD147 might be a bad actor in leukemia, and targeting it could be a good strategy.

In summary, this paper suggests that 4MU fights U937 leukemia cells not by stopping the sticky goo (hyaluronic acid), but by forcing the cells to change their energy habits and by removing a key protein (CD147) that helps them spread. The authors propose that this "HA-independent" mechanism—reprogramming metabolism and disarming the cell's invasion tools—could be a new way to use this existing drug to treat leukemia. While the study provides strong evidence for how 4MU works in the lab, the authors note that more research is needed to see if this translates into a cure for patients, but the findings offer a promising new direction for drug development.